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ABSTRACT:We investigated the independent and interactive impact of the commonAPOE genotype andmarine n-3
polyunsaturated fatty acids (PUFA) on the development of obesity and associated cardiometabolic dysfunction in a
murinemodel. HumanAPOE3 andAPOE4 targeted replacementmicewere fed either a high-fat control diet (HFD)
or a HFD supplemented with 3% n-3 PUFA from fish oil (HFD + FO) for 8 wk. We established the impact of
intervention on food intake, bodyweight, and visceral adipose tissue (VAT) mass; plasma, lipids (cholesterol and
triglycerides), liver enzymes, and adipokines; glucose and insulin during an intraperitoneal glucose tolerance test;
andGlut4andApoEexpression inVAT.HFDfeeding inducedmoreweightgainandhigherplasmalipids inAPOE3
compared to APOE4 mice (P < 0.05), along with a 2-fold higher insulin and impaired glucose tolerance. Supple-
menting APOE3, but not APOE4, animals with dietary n-3 PUFA decreased bodyweight gain, plasma lipids, and
insulin (P < 0.05) and improved glucose tolerance, which was associated with increased VAT Glut4mRNA levels
(P< 0.05).Our findings demonstrate that anAPOE3genotypepredisposesmice to developobesity and itsmetabolic
complications, whichwas attenuated by n-3 PUFA supplementation.—Slim, K. E., Vauzour, D., Tejera, N., Voshol,
P. J.,Cassidy,A.,Minihane,A.M.Theeffect ofdietary fishoil onweightgainand insulin sensitivity isdependenton
APOE genotype in humanized targeted replacement mice. FASEB J. 31, 000–000 (2017). www.fasebj.org
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Apolipoprotein E (APOE) is a multifunctional protein
expressed in many organs and cell types, in particular he-
patocytes, astrocytes, and macrophages (1). In humans, 2
nonsynonymous single nucleotide polymorphisms in the
APOE gene, 388T/C (rs429358) and 526C/T (rs7412), give
rise to 3 common allelic variants, APOE2, APOE3, and
APOE4.Although the etiology is only partially understood,
an APOE4 genotype (;25–30% of white populations) is
traditionally considered detrimental; it is associated with
reduced longevity (2), increased prevalence of Alzheimer
disease (3), and amodestly increased risk of cardiovascular
diseases attributed to higher plasma lipid levels (4) relative
to the common APOE3/E3 genotype. Emerging evidence,
mainly from rodent studies, indicates that the APOE geno-
type may influence bodyweight gain and obesity risk.
Adipocytes have the capacity to synthesize significant
amounts of APOE, which is involved in the expansion of
adipose tissue (AT) (5, 6). The expression of APOE in-
creases linearly upon differentiation of adipocytes (7),
where it is essential for the accumulation of triglycerides
(TG) (8). APOE2/2 mice have a lower fat mass and im-
pairedplasmaTG clearance (9). Information on the impact
of APOE genotype; on AT accumulation, morphology,
and function; and how it interacts with adiposity to
modulate the associated metabolic profile (altered insu-
lin and glucose metabolism, and adipokine and in-
flammatory status) is currently limited and inconsistent
ABBREVIATIONS: ALP, alkaline phosphatase; ALT, alanine aminotransferase;
APOE, apolipoprotein E; AST, aspartate aminotransferase; AT, adipose tissue;
AUC, area under the curve; DHA, docosahexaenoic acid; EPA, eicosapentaenoic
acid; ER, endoplasmic reticulum; FO, fish oil; HDL-C, HDL-cholesterol; HFD,
high-fat diet; HOMA, homeostatic model assessment; IGT, impaired glucose
tolerance; IPGTT, intraperitoneal glucose tolerance test; IR, insulin resistance;
LC, long chain; NEFA, nonesterified fatty acid; PPAR-g, peroxisome proliferator-
activated receptor g; PUFA, polyunsaturated fatty acid; qRT-PCR, quantitative
RT-PCR; TC, total cholesterol; TG, triglycerides; TR, targeted replacement; VAT,
visceral adipose tissue
1 Correspondence: Department of Nutrition and Preventive Medicine,
Norwich Medical School, University of East Anglia, Norwich NR4 7UQ,
United Kingdom. E-mail address: a.minihane@uea.ac.uk
This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
(http://creativecommons.org/licenses/by-nc/4.0/) which permits noncom-
mercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
doi: 10.1096/fj.201600921RR
This article includes supplemental data. Please visit http://www.fasebj.org to
obtain this information.
0892-6638/17/0031-0001 © The Author(s) 1
 The FASEB Journal article fj.201600921RR. Published online December 2, 2016.
 Vol.,  No. , pp:, December, 2016The FASEB Journal. 139.222.81.188 to IP www.fasebj.orgDownloaded from 
(10–13). No comprehensive analysis (representing the
primary study endpoint) of the impact ofAPOE genotype
on bodyweight or AT volume or topography is currently
available in humans. In targeted replacement (APOE TR)
mice, which retain the murine regulatory sequences
but solely express the human APOE3 or APOE4 genes,
Huebbe et al. (11) reportedAPOE3 as the thrifty genotype
associated with greater weight gain and abdominal AT
mass after a high-fat diet (HFD). The lower weight gain
inAPOE4 animalswas coupledwith higherAT fatty acid
mobilization and up-regulated fatty acid b-oxidation
genes in skeletal muscle (11).
The long-chain n-3 polyunsaturated fatty acids (LC n-3
PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), which are found in oily fish and fish oil
(FO) supplements, have been shown to exert potent anti-
obesogenic and insulin-sensitizing effects in murine
models [reviewed in (14, 15)]. In various studies, LC n-3
PUFA supplementation has been shown to reduce the
accumulation of body fat (16) and to prevent or reverse
insulin resistance (IR) (17) after a HFD challenge. How-
ever, the effects of LC n-3 PUFA on bodyweight and
insulin sensitivity in humans remains controversial
(reviewed in refs. 18, 19). The considerable intra- and
interstudy variability and lack of consistency in the re-
sponse is likely to be in part due to the genetic variability
bothwithin and between populations. Although the role
ofAPOE in adipocytemetabolism iswell defined and the
APOE genotype has been shown to determine LC n-3
PUFA status (20) and the response of plasma lipids to LC
n-3 PUFA intervention (21), the impact of genotype on
the responsiveness of adiposity and its associated phe-
notype to altered LC n-3 PUFA intake are unknown.
Using the HFD-fed APOE3 and APOE4 TR mouse
models, in addition to characterizing APOE genotype–
adiposity associations,we investigated the impact of LCn-3
PUFA supplementation on bodyweight gain, visceral adi-
pose tissue (VAT) mass, glucose tolerance, and biomarkers
of insulin action according to APOE genotype status.
MATERIALS AND METHODS
Study approval
All experimental procedures and protocols used in this study
were reviewed and approved by theAnimalWelfare andEthical
Review Body and were conducted within the provisions of the
Animals (Scientific Procedures) Act of 1986 and the Guiding
Principles for Preparing for and Undertaking Aseptic Surgery (Lab-
oratory Animal Science Association).
Animal experimental design and
dietary treatments
Forty 13- to14-wk-old male human APOE3 [B6.129P2-
Apoetm2(APOE*3)MaeN8] andAPOE4 [B6.129P2-Apoetm2(APOE4)Mae
N8] TRmice homozygous for the humanAPOE3 orAPOE4 gene
(Taconic Farms, Germantown, NY, USA) (22) were randomly al-
located to a HFD (45 kcal% from fat, 0.02% [w/w] cholesterol;
Research Diets, New Brunswick, NJ, USA) or a HFDwith 3% LC
n-3 PUFA (HFD + FO; Research Diets) for 8 wk (n = 10 mice per
group) (Supplemental Table S1). A HFD control diet was used to
mimic human Western human dietary patterns. The HFD + FO
contained a blend of Menhaden FO and docosahexaenoic acid
triglyceride (DHAsco oil; DSM Nutritional Products, Columbia,
MD, USA), providing 12 g EPA and 18 g DHA per kg of diet
(Supplemental Table S1). Mice were maintained in a controlled
environment (21°C; 12 h light–dark cycle; light from 7:00 AM).
Food pellets were replaced every other day to avoid oxidation of
the bioactive components.
At the end of wk 8, animals were sedated with a mixture of
isoflurane (1.5%), nitrous oxide (70%), and oxygen (30%), and
blood samples were collected by cardiac puncture into lithium–
heparin–coated microtubes (Sarstedt, Leicester, United King-
dom), followed by transcardiac perfusion of ice-cold saline
containing heparin (10 U/ml; Sigma-Aldrich, St. Louis, MO,
USA). Plasma samples were isolated by centrifugation at 2000 g
for 10 min, and the VATwas snap frozen and stored at280°C.
Intraperitoneal glucose tolerance test
Forty-eight hours before the animals were humanely killed, an in-
traperitoneal glucose tolerance test (IPGTT)wasperformed.After a
16-h overnight brief starvation period, which was used to deplete
liver glycogen stores and minimize variability in blood glucose, a
baseline tail blood sample was collected before mice received an
intraperitoneal injection of D-glucose (2 g/kg bodyweight) (23).
After injection,bloodsamples (2ml)were collectedat10, 20, 30, 60,
and 120 min, and glucose concentrations were determined using
an AlphaTrak 2 glucometer (Abbott Laboratories, Lake Bluff, IL,
USA).Additional blood samples (20ml) for insulin determination
were collected at baseline and at 15 and 120 min into EDTA-
coated Microvette tubes (Sarstedt). Tubes were centrifuged at
2000 g for 15 min at room temperature, and resulting plasma
samples were snap frozen and stored at 280°C. Insulin concen-
trationsweredeterminedusinga commercialELISAkit following
the manufacturer’s instructions (Crystal Chem, Downers Grove,
IL, USA). Whole-body IR was estimated using the homeostatic
model assessment (HOMA)-IR index. Area under the curve
(AUC) was calculated by the trapezoidal method (24).
Biochemical analysis
Plasma total cholesterol (TC), HDL-cholesterol (HDL-C), TG,
alanine aminotransferase (ALT), alkaline phosphatase (ALP),
and aspartate aminotransferase (AST) concentrations were
measured using commercial IL Test assays (Instrumentation
Laboratory UK, Warrington, United Kingdom), and non-
esterified fatty acid (NEFA) levels were measured using the
commercial colorimetric assay (Randox Laboratories, Crumlin,
United Kingdom) on the ILab-650 analyzer (Instrumentation
Laboratory UK). Plasma levels of the liver enzymes ALT, ALP,
and AST were assessed to evaluate liver function. Plasma non-
HDL-C levels, consisting of LDL-cholesterol plus very low
density lipoprotein-cholesterol, were calculated by subtracting
HDL-C from TC. The plasma levels of the 2 major adipokines
involved in appetite and metabolic control, leptin and adipo-
nectin, were analyzed with commercial ProcartaPlex Simplex
Immunoassays (eBiosciences, Hatfield, United Kingdom) using
the Luminex 200 System (Luminex, Austin, TX, USA). Plasma
levels of the antiinflammatory and insulin sensitizing cytokine
IL-10 were analyzed using a commercial Mouse IL-10 ELISA
Ready–Set–Go kit (eBiosciences). The moisture content of 50 mg
of total feces was determined, with total lipid content expressed
on a dry weight basis (25). Total lipids were extracted from 50 to
200 mg of epididymal AT with chloroform/methanol (2:1 v/v)
containing 0.01% butylated hydroxytoluene (Sigma-Aldrich) as
an antioxidant (26). Fatty acid analysis of total lipids was con-
ducted as previously described (27).
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RNA isolation and real-time PCR
Total RNAwas isolated fromVATusingAmbionTrizol reagents
(ThermoFisherScientific, Loughborough,UnitedKingdom).The
primer sequences are given in Supplemental Table S2. One mi-
crogram of total RNAwas treated with DNase I (Thermo Fisher
Scientific) andused for cDNAsynthesis usingOligo (dT) primers
and SuperScript II Reverse Transcriptase (Thermo Fisher Scien-
tific). Real-time quantitative RT-PCR (qRT-PCR) reactions were
performed with Precision qPCR MasterMix (PrimerDesign,
Southampton, United Kingdom) using SYBR green detection
technology on the Applied Biosystems 7500 Real-Time PCR
system (Thermo Fisher Scientific). Results are expressed as rela-
tive quantity scaled to the average across all samples per target
gene and normalized to the reference genes actin, b (Actb),
ATP synthase, H + transporting mitochondrial F1 complex, b
subunit (Atp5b), and glyceraldehyde-3-phosphate dehydro-
genase (Gapdh).
Statistical analysis
All values are presented as means 6 SEM. A power calculation
was conducted to calculate the number of animals needed to
detect a standardized mean difference of 1.45 for a 2-sample
comparison of means with power of 90% at significance level of
a=0.05,whichyielded10miceperAPOEgenotype3dietgroup.
Datawereanalyzedby2-wayANOVAfollowedbycomparisons
of APOE3-HFD, APOE3-HFD + FO, APOE4-HFD, and APOE4-
HFD + FO groupswith Bonferroni correction when a significant
overall genotype 3 diet interaction were detected. Data with
multiple timepoints were analyzed by repeated-measures
ANOVA. Data not following a normal distribution (food intake
and ALT) detected by the Kolmogorov-Smirnov test, or having
unequal variances detected by Levene’s test, were assessed by
nonparametric tests. Statistical analysis of themRNA expression
levels was done with log-transformed values. All statistical
analyses were performed by SPSS 18.0 (IBM SPSS, Chicago, IL,
USA), with the threshold of significance of P, 0.05.
RESULTS
The expected FO-induced enrichment of AT EPA and
DHA was observed, with a genotype 3 diet interaction
evident for EPA (P, 0.05) but not forDHAor total LCn-3
PUFA (Supplemental Table S3).
LC n-3 PUFA modulate the APOE3 genotype
predisposition to higher weight gain and
increased VAT expansion
To investigate whether APOE genotype interacts with di-
etary LC n-3 PUFA to determine adiposity and the pre-
disposition to diet-induced obesity, we compared the
change in bodyweight, VAT weight, food intake and ef-
ficiency, and fecal lipid content in APOE3 andAPOE4 TR
mice after a HFD or a HFD + FO for 8 wk. There was a
significant effect of diet (P , 0.01) on bodyweight gain
(Fig. 1A) and a trend toward a different effect according to
APOE genotype (P = 0.10), with more weight gain in
APOE3-HFD relative to APOE3-HFD + FO and APOE4-
HFD + FO from 3 wk onward.
There was a significant effect of diet (P , 0.05) and
APOEgenotype (P, 0.05) onVATweight (Fig. 1B),which
was 17%higher inAPOE3mice compared toAPOE4mice,
and 9% higher in mice fed theHFD + FO compared to the
HFD.
APOE3 mice fed the HFD had 20% higher food intake
compared to the other 3 groups, and dietary LC n-3 PUFA
resulted in an 12% reduction in food intake inAPOE3mice
(P , 0.05; Fig. 1C). A lower fecal lipid content (+/2 FO),
indicative of higher lipid absorption, was evident in
APOE3 animals (Table 1).
Food efficiencies were not significantly different be-
tween groups, although there was a trend toward lower
values after HFD + FO feeding (Fig. 1D).
APOE3 mice fed the HFD had 25-fold lower Apoe
mRNAlevels inVATcompared to theother 3groups,with
a significant increase after FO intervention (Fig. 1E).
LC n-3 PUFA attenuation of blood lipids is
dependent on APOE genotype
Diet interactedwithAPOE genotype to determine plasma
TG (P , 0.001), TC (P , 0.001), non-HDL-C (P , 0.001),
and NEFA (P , 0.05) (Table 2). Compared to the other
groups, APOE3 mice fed a HFD had approximately 60%
higher plasma TG levels. Dietary LC n-3 PUFA decreased
plasma TG, TC, HDL-C, non-HDL-C, and NEFA levels in
APOE3 mice (P , 0.05). In APOE4 mice, dietary LC n-3
PUFA decreased plasma TC and HDL-C (P, 0.05).
LC n-3 PUFA decrease ALT and increase IL-10
in mice
Higher plasma ALT levels after the HFD were evident in
APOE3mice, with FO feeding reducing the concentration
by 2.5-fold in APOE3 animals only (P , 0.05). There was
no effect of genotype or diet on plasma ALP and AST
levels (Table 2). A significant overall FO induced increase
in IL-10 was evident, with increases significant in APOE4
mice only (P = 0.027, Table 2). There were no significant
genotype- or diet-mediated differences in the plasma
adiponectin or leptin levels.
LC n-3 PUFA mitigate IR through increased
VAT expression of Glut4 in APOE3 mice
There was no difference in fasting plasma glucose levels
(Fig. 2A) between the intervention groups. APOE3 mice
fed the HFD had higher fasting plasma insulin levels
compared to the mice fed a HFD + FO (P, 0.05; Fig. 2B),
which was associated with a higher HOMA-IR (P, 0.05;
Fig. 2C). Given the role of the insulin-regulated glucose
transporter Glut4 in tissue insulin-stimulated glucose up-
take, Glut4 mRNA expression levels in VAT were in-
vestigated. APOE3 mice fed a HFD had the lowest Glut4
mRNAlevels, butdietaryLCn-3PUFAresulted in a5-fold
increase in Glut4 mRNA levels (P , 0.05; Fig. 2D). The
beneficial effect of FO on Glut4 expression was not ob-
served in APOE4mice.
There was no difference in the plasma glucose levels
during the IPGTT (Fig. 3A, C). Diet had a significant effect
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on plasma insulin levels (P , 0.001; Fig. 3B), which was
dependent onAPOEgenotype (P, 0.05).APOE3mice fed
a HFD had significantly higher plasma insulin levels
compared to themice fed aHFD+FO (Fig. 3B),whichwas
reflected in the plasma insulin AUC (P = 0.13; Fig. 3D).
DISCUSSION
With overweight and obesity affecting almost 2 billion
people worldwide, there is widespread interest in the
identification of dietary strategies forweightmanagement
and themitigation of itsmetabolic complications (28). The
cardiovascular benefits of LCn-3PUFAarewell described
(29), but their effects on adiposity and insulin sensitivity
remain controversial. Our findings demonstrate that an
APOE3genotypepredisposesmice todevelopobesity and
its metabolic complications, which was attenuated by n-3
PUFA supplementation.
Consistent with 2 previous studies using this mouse
model, we showed that APOE3 animals develop diet-
inducedobesity, dyslipidemia, and IRwhile eating aHFD,
while theAPOE4miceareprotected (10, 11).Here, ahigher
food intake, which implies an increase in appetite that has
TABLE 1. Total lipid content (% dry weight basis) of fecal samples after 8 wk of feeding
APOE3-HFD APOE3-HFD + FO APOE4-HFD APOE4-HFD + FO P
3.2 6 0.1 3.1 6 0.0 4.0 6 0.1 4.1 6 0.3 0.001, G
Values are expressed as means 6 SEM for 3 extractions from pooled feces samples of 10 animals per
group. ANOVA was conducted to establish signiﬁcance of impact of APOE genotype (G), diet (D), and G3D
interactions using untransformed data and were considered statistically signiﬁcant when P , 0.05.
Figure 1. Development of diet-induced obesity in APOE3 and APOE4 TR mice fed HFD or HFD + FO for 8 wk. A) Bodyweight over
8 wk. Bodyweights were signiﬁcantly different between diets but not APOE genotypes (P , 0.05, diet; P = 0.19, genotype; P = 0.10,
diet 3 genotype; ANOVA). *P , 0.05 APOE3-HFD is different from APOE3-HFD + FO and APOE4-HFD + FO. B) VAT weight at
8 wk. VAT weights were signiﬁcantly different between diets and APOE genotypes (P , 0.05, diet; P , 0.05, genotype; P = 0.94,
diet 3 genotype; ANOVA). *P , 0.05. C) Average food intake over 8 wk. Average food intake was signiﬁcantly different between
groups (P , 0.05, diet 3 genotype; Kruskal Wallis). *P , 0.05. D) Average food efﬁciency over 8 wk. E) Relative mRNA
expression of apolipoprotein E (Apoe) in VAT. Relative mRNA expression of Apoe was signiﬁcantly different between groups
(P = 0.44, diet; P = 0.61, genotype; P , 0.001, diet 3 genotype; ANOVA). Data are shown as means 6 SEM, n = 9–10 mice per
group. ***P , 0.001. APOE3-HFD is different to other groups. APOE, apolipoprotein E; HFD, high-fat diet; HFD + FO, HFD
containing 30 g EPA + DHA/kg of diet.
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been previously proposed (11), and higher fat absorption,
underlie the greater weight gain in APOE3 animals. Di-
etaryLCn-3PUFAdecreased food intakeandbodyweight
gain especially in APOE3 mice, suggesting that LC n-3
PUFAmay improve satiety andmay inpart counteract the
physiologic effect of the APOE3 genotype. Leptin is an
importantAT-derived regulator of food intake,which acts
on receptors in the hypothalamus to decrease hunger and
stimulate satiety. Higher circulating levels of leptin have
been associated with an increase in body mass index and
body fat in humans (30) and have been shown to increase
during prolonged hyperinsulinemia (31). Although we
observeda trend toward reduced leptinafter FO feeding, it
did not reach statistical significance.
APOE3 mice fed the HFD had a higher average food
intake and lipid absorption but a similar overall food ef-
ficiency compared to the other 3 groups, which is in ac-
cordance with their greater bodyweight gain. However,
on theHFD+FOdiet, a lackof difference inweight gain in
APOE3 relative to APOE4 animals despite higher food
TABLE 2. Plasma biochemistry in APOE3 and APOE4 mice after 8 wk of feeding
Biochemistry APOE3-HFD APOE3-HFD + FO APOE4-HFD APOE4-HFD + FO
P
G D G 3 D
Plasma lipid
TG (mg/dl) 128 6 10a 71 6 6b,c 81 6 9b 84 6 5b,c ,0.05 ,0.01 ,0.001
TC (mg/dl) 137 6 3a 91 6 4b,d 119 6 5c 100 6 5b,d ,0.05 ,0.01 ,0.001
HDL-C (mg/dl) 116 6 3a 99 6 7b 107 6 6a 82 6 4c ,0.05 ,0.001 NS
Non-HDL-C (mg/dl) 20 6 2a 10 6 1b 12 6 1b,c 17 6 2a,c NS NS ,0.001
NEFA (mM) 1.7 6 0.1a,c 0.7 6 0.1b 1.3 6 0.2a,c 0.9 6 0.1b,c NS ,0.001 ,0.05
Liver enzymes
ALT (IU/L) 49 6 8a 21 6 1b 31 6 8a,b 17 6 1b ,0.05 ,0.01 ,0.001
AST (IU/L) 106 6 12 123 6 21 105 6 14 79 6 7 NS NS NS
ALP (IU/L) 63 6 4 49 6 3 62 6 5 62 6 5 NS NS NS
Adipokines/ cytokines
IL-10 (pg/ml) 301 6 55a 378 6 43 a,b 278 6 35a 536 6 138b NS ,0.05 NS
Adiponectin (mg/ml) 194 6 22 183 6 29 207 6 22 214 6 18 NS NS NS
Leptin (ng/ml) 6.7 6 0.5 5.1 6 0.5 5.5 6 0.8 4.4 6 0.4 NS NS NS
Values are expressed as means 6 SEM (n = 7–10 mice per group). Lipids, liver enzymes, and adipokines/cytokines were measured in
nonfasted plasma samples. Two-way ANOVA followed by Bonferroni correction was conducted to establish the signiﬁcance of the impact of APOE
genotype (G), diet (D), and G 3 D interactions on plasma lipids, liver enzymes, and adipokines/cytokines. Letters (a–c) indicate differences
between groups. P , 0.05.
Figure 2. Markers of insulin sensitivity in the
unfed state of APOE3 and APOE4 TR mice
after 8 wk on HFD or HFD + FO. A) Plasma
glucose. B) Plasma insulin. C) HOMA-IR index.
D) Relative mRNA levels of insulin-regulated
glucose transporter Glut4 in VAT. Data are
shown as means 6 SEM, n = 9–10 mice per
group. Fasting plasma insulin (P = 0.64, diet;
P = 0.26, glucose; P , 0.05, diet 3 genotype;
ANOVA), HOMA-IR (P = 0.58; P = 0.23;
P , 0.05, diet 3 genotype; ANOVA), and rela-
tive mRNA levels of Glut4 (P = 0.83; P = 0.41;
P , 0.01, diet 3 genotype; ANOVA) were
signiﬁcantly different between groups. *P, 0.05,
**P , 0.01. Glut4, solute carrier family 2 (facil-
itated glucose transporter) member 4 (Slc2a4).
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intake, higher lipid absorption, and similar food efficiency
is indicative of a higher energy expenditure. This is un-
likely to be attributed to greater activity in these mice, as
physical activity—although contributing to daily energy
expenditure—has no effect on total energy expenditure in
mice housed below their thermoneutrality (32). Two re-
cent studies indicated that inmice, theAPOE4 genotype is
associated with an increased basal mitochondrial uncou-
pling and fatty acid oxidation compared to the APOE3
genotype (11, 33). LC n-3 PUFA increase mitochondrial
biosynthesis and oxidative capacity, as well as fatty acid
oxidation (14). Thus, we speculate that in APOE3 mice,
although having a lower basal rate, an LC n-3 PUFA in-
duction of mitochondrial activity may explain the lower
weight gain in the group fed a HFD + FO relative to the
HFD group, and the apparent higher energy expenditure
compared to APOE4 mice fed the HFD + FO. Further
studies are needed to fully elucidate differences in mito-
chondrial function betweenAPOE3 andAPOE4mice and
their response to dietary lipids.
TheAPOE4 genotypewasassociatedwith a lowerVAT
mass compared to the APOE3 genotype in the current
study. APOE is involved in AT expansion, with its ex-
pression levels increasing on differentiation and correlat-
ingwith the lipid content in adipocytes (7, 34). A potential
mechanism linking APOE genotype to adipogenesis sig-
naling pathways is endoplasmic reticulum (ER) stress,
which is increasingly recognized as one of the underlying
causesofmetabolicdysfunction inobesity (35).Nutritional
excess and an accumulation of unfolded and misfolded
proteinswithin the ER are 2 known causes of the ER stress
triggering unfolded protein response, which activates
metabolic and inflammatory signaling pathways (35). The
APOE4 protein has a lower protein stability and is in-
creasingly recognized as an abnormally folded protein in
the ER compared to the APOE3 protein. Although Dose
et al. (36) recently reported little influence of APOE geno-
type on hepatic stress response pathways, an APOE4 ge-
notype resulted in an increased ER stress response in both
macrophages and astrocytes (37). The increased ER stress
would have a negative effect on the formation of new
adipocytes (adipogenesis). This theory is supported by
findings fromArbones-Mainar et al. (10),whoshowed that
APOE4mice had fewer but larger adipocytes after 8wk of
HFD feeding compared to APOE3 mice, suggesting that
formation of new adipocytes rather than adipocyte TG
accumulation is contributing to the reducedATexpansion
inAPOE4mice. Dietary LCn-3PUFAwas associatedwith
a higherVATmass in bothAPOE3 andAPOE4mice in the
current study, which could be mediated by peroxisome
proliferator-activated receptor g (PPAR-g) signaling. LC
n-3 PUFA function as ligands for PPAR-g, with PPAR-g
beingboth sufficient andessential for adipogenesis, aswell
as required for the initiation and maintenance of the
Figure 3. Glucose and insulin levels during an IPGTT performed at 8 wk in APOE3 and APOE4 TR mice fed HFD or HFD + FO. A)
Plasma glucose levels at times 0, 10, 20, 30, 60, and 120 min. B) Plasma insulin levels at times 0, 15, and 120 min. C) AUC for
plasma glucose. D) AUC for insulin. Data are shown as means 6 SEM, n = 9–10 mice per group. Plasma glucose levels were
signiﬁcantly different between diets but not APOE genotypes (P , 0.05, diet; P = 0.90, genotype; P = 0.63, diet 3 genotype;
ANOVA). Plasma insulin levels were signiﬁcantly different between diets, which was dependent on APOE genotype (P , 0.001,
diet; P = 0.08, genotype; P , 0.05, diet 3 genotype; ANOVA). *P , 0.05 APOE3-HFD is different from APOE3-HFD + FO and
APOE4-HFD + FO.
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differentiated state in adipocytes (38) and associated with
increased APOE (39).
In this study,APOE3butnotAPOE4micedeveloped IR
and impaired glucose tolerance (IGT) when fed a HFD,
whichwas associatedwith higher plasma insulin, TG, and
NEFA levels. Overall, the increased insulin production to
clear plasmaglucose in both the fasting and thenonfasting
state in the APOE3 mice fed the HFD indicates IGT and
reduced insulin sensitivity. Consistent with a greater hu-
man blood mononuclear cell inflammatory cytokine re-
sponse to FO according in human APOE4 carriers (40),
here higher FO-induced IL-10 was evident in APOE4
animals, which may have contributed to the insulin-
sensitizing effects. Congruent with this idea, it has been
shown thatmice treatedwith IL-10 did not become insulin
resistant when exposed to either IL-6 or lipid infusions
(41). Furthermore, Lumeng et al. (42) have reported that
IL-10-treated 3T3L1 adipocytes are protected from
TNF-induced cellular IR.
Our finding are not consistent with the only previous
study reporting thatAPOE4 andnotAPOE3mice develop
IGT after 8 wk of HFD feeding (10). The reasons for these
apparently contradictory findings are unknown, but they
may relate to differences in the composition of the diets.
Our diet contained no sucrose, whereas Arbones-Mainar
et al. (10) used a HFD containing a high (34.1%) sucrose
content, with sucrose known to promote the development
of IR and diabetes.
Although metabolic interdependency cannot be estab-
lished, the observed prevention of IR and IGT by dietary
LC n-3 PUFA in APOE3 mice could be the result of the
reduction in bodyweight. The insulin-regulated GLUT4
plays an important role in the insulin-stimulated glucose
uptake inmuscle andAT (43), with its protein levels being
regulated at the transcriptional level (44). We demon-
strated that LC n-3 PUFA increased the Glut4 mRNA
levels in the VAT of APOE3 mice, which, although may
reflect increased GLUT4 turnover (45), likely suggests
increased GLUT4 protein levels that could account for
the observed beneficial effects on glucose tolerance.
Furthermore, LC n-3 PUFA improve insulin signaling
via the insulin receptor by inhibition of the NF-kB and
JNK pathways, which results inmore effective insulin-
stimulated GLUT4 translocation from intracellular
vesicles to the cell membrane and increased glucose
uptake (46). Surprisingly, the beneficial effects of LC
n-3 PUFA on Glut4mRNA levels were not observed in
APOE4 mice.
The strengthsof the current studywere theuse of adiet-
induced obesity approach relevant to human obesity and
dietary patterns, and the use of IPGTT to assess insulin
sensitivity.
Human data on the association between APOE geno-
type and bodyweight are currently inconsistent (47–52).
Limited studies suggest that APOE genotype interacts
with bodymass index to determinemetabolic parameters
such as plasma cholesterol, glucose, and insulin (13, 48).
Although studies in APOE TR mice increasingly show an
effect of APOE genotype on bodyweight, the effect in hu-
mans is likely to be more modest. Furthermore, human
studies investigating energy metabolism according to
APOE genotype are currently lacking; more research is
needed in this area. The beneficial effects of LC n-3 PUFA
on bodyweight and composition in humans remain con-
troversial, although a recent meta-analysis indicated that
LC n-3 PUFA supplementation results in a modest 590 g
reduction in bodyweight, 0.24 kg/m2 reduction in body
mass index, 0.8 cmdecrease inwaist circumference, and
0.5% decrease in body fat in adults over 3 wk to 3 yr
intervention periods (53). Although subtle, such effects
on weight maintenance and adiposity could contribute
to amelioration of the typical gain of 2 kg per decade
evident in adult populations (54). The effect of LC n-3
PUFA on glucose homeostasis and insulin sensitivity in
humans is also inconsistent (18, 19), which is likely to be
in large part attributable to genetic variability of par-
ticipants, with the current study indicating that APOE
genotype may be important. AlthoughAPOE genotype
has been shown to affect LC n-3 PUFAmetabolism and
bioavailability (20, 33, 55) and to determine the plasma
lipid response to LC n-3 PUFA supplementation (21, 56),
its impact on the response of glucose and insulin is
currently unknown. Future prospective cohort and in-
tervention studies in humans (or retrospective analyses
of existing cohorts) that capture APOE genotype status
are therefore warranted to determine whether the effi-
cacy of LC n-3 PUFA in reducing bodyweight and im-
proving insulin sensitivity varies according to this
common genotype.
In summary, our results indicate that although the
APOE4 allele has been associated with risk of cardiovas-
cular disease, in an obesogenic environment, it may be
protective againstweightgainand its associatedmetabolic
complications. Furthermore,wepropose that in thosewith
the common APOE3/E3 genotype, LC n-3 PUFA in-
tervention may mitigate the adiposity and loss of insulin
action associatedwith a high fat intake. These findings are
of wide public health relevance, given the prevalence of
the APOE3 and APOE4 alleles. An important direction
for future research is to reproduce these findings in
humans.
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